Auxesis Pharma is a Swedish pharmaceutical company developing innovative medicines for localized pain and irritation in the skin — for both humans and animals.
Our pharmaceutical development in Sweden is built on proprietary patents, long-term research, and a clear vision: to redefine the therapeutic category of “pain and irritation in the skin” with science at its core.
Auxesis Pharma is a pharmaceutical company determined to change how pain and irritation in the skin are treated. With science as our foundation and a breakthrough patent, we develop innovative medicines that can rapidly relieve and remove skin pain — in formats that are easy to use for both consumers and professionals.
What began as a research project has evolved into a Swedish pharmaceutical group with proprietary patents, planned production, and a growing portfolio of medicines for both humans and animals.
We focus on the category of localized pain and irritation in the skin, where the need for effective and accessible treatments is significant — in both human and veterinary medicine.
More about us
Parent company and central securities register company that holds the rights to the Group’s patents in selected medical research areas. The focus is to develop innovative medicines for localized pain and irritation in the skin — for both humans and animals.
Subsidiary founded in 2024. The company is responsible for prototype manufacturing and will hold a license to produce and market our medical products in the Nordic region, as well as manage licenses for the rest of the world. A dedicated factory will be established in the future to ensure quality, traceability, and efficient deliveries.
www.auxesismedtech.comSubsidiary focused on the animal care market, primarily dogs and livestock. Here we develop topical solutions for skin pain and irritation in animals, with the aim of reducing suffering and the need for systemic medications.
This means we aim to:
This vision shapes everything from our patent strategy and product development to how we approach manufacturing and choose partnerships.
This means we focus on:
Our mission ensures we take innovation all the way from the laboratory to a finished product — with quality and evidence at the core.
Behind Auxesis is a multidisciplinary team with extensive experience in pharmaceutical development, research, entrepreneurship, and industry.
Together, we transform scientific discoveries into market-ready pharmaceutical products, with science, quality, and patient benefit at the core of everything we do.
Chairman of the Board & Founder
Roar Adelsten is the founder of Auxesis Pharma Holding AB, Auxesis MedTech AB, and Auxesis Animal Care AB.
He has nearly 30 years of experience in the pharmaceutical industry, serving as CEO, Field Manager, and Medical Consultant, including positions at Pfizer AS in Norway. He has also worked in Sweden, Norway, and the United States within reconstructive orthopedic surgery, orthopedics, surgical instruments, and joint and bone arthroplasty.
B.Sc. Medical Science, Toxicology, IHM Business School
Peter Åberg is CEO, Business Advisor, and a member of the ASA.P pharmaceutical development team.
He has more than 20 years of leadership experience in medtech, pharmaceuticals, and manufacturing industries, serving in executive positions including CEO and Chief Sustainability Officer.
Peter holds a Bachelor's degree in Medical Science with specialization in Toxicology, is a United Nations representative, and works with international sustainability standards in leadership, environmental management, and business development.
Board Member & Business Developer in Cosmeceuticals
Anna Tenstam has more than 30 years of international senior leadership experience within pharmaceuticals, medical technology, and medical aesthetics. She has held executive positions in several global companies and has participated in multiple acquisitions and successful exits alongside companies such as Johnson & Johnson and Galderma.
She currently serves as Senior Advisor, focusing on fundraising and strategic business development for pharmaceutical and medical technology companies. Previous senior positions include Q-Med, Bristol Myers Squibb, Pharmacia, and Lederle Cyanamid.
Anna has extensive board experience, including Q-Med AB and approximately 25 additional board assignments. She is also active in several professional organizations and networks, including the Aesthetic Industry Association (AIA), STING, and VILDA.
Board Member
Lars-Olof Peterson is an experienced business advisor with extensive expertise in executive management, corporate strategy, and business development. He has held several executive leadership positions, including CEO roles within the medical technology industry, and has served on the board of Swedish Medtech.
He has also worked extensively with international standards and regulatory affairs through assignments for ISO and SIS.
Lars-Olof is currently CEO of VD-stödet i Sverige AB.
Head of Brand & Product Strategy
Helena Adelsten leads the development of Auxesis' brands and product platforms, with responsibility for brand strategy, concept development, product identity, design, and digital communications.
She has played a key role in creating brands such as Cutivelle™ and Lenvée™, leading projects from concept and brand strategy to digital presence, marketing materials, and commercial positioning. With an academic background in IT and Economics, she combines technology, design, and business development to strengthen the company's innovation platform.
Intellectual Property, Commercial Agreements & Dispute Resolution
Peter Hedberg specializes in intellectual property, commercial agreements, and dispute resolution. He is an expert in intellectual property law, marketing law, and commercial legal matters, with extensive experience providing strategic legal advice.
He has worked with IP strategies, infringement proceedings, and commercial matters for both Swedish and international companies and is a trusted advisor in complex business transactions.
Project Manager, CoxyPet
Robert Lind is Project Manager for CoxyPet with an academic background in political science, law, psychology, and sociology. He holds Master's-level degrees in Political Science/Law and Psychology/Sociology.
He has worked within the Scania Group in project management and international customer relations, and has also held assignments with national radio and television broadcasters in Poland.
Medical Advisor and Developer, Auxesis Pharma AB
Professor and physician with extensive experience and internationally recognized expertise in topical medicine, intensive care, and burn medicine.
Former Director of the Burn Center and Chief of Staff at the Department of Anesthesiology and Intensive Care, Linköping University Hospital (1999–2004).
President of the European Burns Association (EBA) (2007–2009).
Director of Research and Development at the Swedish Intensive Care Registry (2009–2013).
Deputy Vice-Chancellor of Linköping University (2015–2018).
President of the International Society for Burn Injuries (ISBI).
Former member of the American Burn Association Burn Center Verification Committee.
Supervisor of more than 40 PhD students and Principal Investigator in more than 300 clinical trials, ranging from Phase I to Phase IV.
Author and co-author of more than 350 peer-reviewed scientific publications, including books and book chapters.
RegSmart Life Science
M.Sc. Pharm., PhD
Agneta Larhed has served as Regulatory Advisor to Auxesis since August 2024, focusing on pharmaceutical quality and regulatory requirements for clinical development.
Her work includes quality requirements for both active pharmaceutical ingredients and finished medicinal products prior to clinical trials and marketing authorization applications.
She has previously held senior positions in research and development, formulation development, and regulatory authorities, working extensively with pharmaceutical quality and regulatory approval processes.
Zelmic
M.Sc. Chemical Engineering, Project Manager
Susanna Liljedahl has been a member of the ASA.P pharmaceutical development team since September 2024, with responsibility for formulation development and manufacturing of the Investigational Medicinal Product (IMP).
She is Project Manager at Zelmic and has more than ten years of experience as a researcher and project manager, including positions at AstraZeneca, specializing in pharmaceutical formulation and process development.
Susanna has served on executive management teams and led product and process development across several companies, with strong expertise in scalable development and quality-driven manufacturing.
RegSmart Life Science
Chief Medical Officer
Marie Gårdmark (M.Sc. Pharm., PhD) has served as Regulatory Advisor to Auxesis since August 2024, focusing on preclinical and clinical development.
She has extensive experience from senior positions within both regulatory authorities and pharmaceutical research and development, with particular expertise in global regulatory strategies, due diligence, and scientific advice procedures within Europe and the United States.
Marie has broad experience across preclinical and clinical research, primarily within early-stage drug development and strategic development planning.
Zelmic develops topical and transdermal pharmaceutical formulations and supports Auxesis in formulation development. They are an experienced, privately owned CRO and CDMO.
To ZelmicAFRY supports Auxesis in planning and designing a sustainable production model. AFRY assists with medical research, regulatory processes and the development of future production capacity.
To AFRYAuxesis collaborates with EIP on patents for ASA.P® and forthcoming patent applications. EIP has broad international expertise in drafting strong patent applications worldwide.
To EIPClinical Trial Consultants (CTC) is a specialized consultancy in clinical development, supporting pharmaceutical and medtech companies throughout the clinical process. With deep medical and regulatory expertise, CTC contributes to efficient study design, execution, and quality assurance across early and late clinical phases.
To CTCAuxesis uses Edlund & Partners as its audit firm. Edlund & Partners has the competence, experience, and authorization to support companies in connection with stock exchange listings.
To EdlundRegSmart Life Science AB supports Auxesis with regulatory matters related to the commercialization of ASA.P®. They help navigate a complex and evolving regulatory landscape.
To RegSmartIQVIA and Svensk Läkemedelsstatistik provide accurate and comprehensive analyses of the pharmaceutical industry in Sweden and globally. Through thorough analysis and tailored consulting services, Auxesis gains valuable insights for decision-making.
To IQVIARamberg Advokater in Stockholm is a full-service law firm with specialist expertise across multiple practice areas. Ramberg provides legal support to Auxesis, including commercial law, trademark matters, and a wide range of regulatory legal issues worldwide.
To RAMBERGDigital customer support
Hello! I can help you with common questions about Auxesis Pharma, products, news and shareholder information. What would you like to know?
